Evolution of SARS-CoV-2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: Impact on clinical outcomes.

COVID-19 Delta variant Omicron BA.1 and BA.2 SARS-CoV-2 variants of concern disease severity hospitalized patients

Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
06 2023
Historique:
revised: 18 04 2023
received: 21 09 2022
accepted: 16 05 2023
medline: 30 5 2023
pubmed: 29 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

Despite the higher transmissibility of Omicron Variant of Concern (VOC), several reports have suggested lower risk for hospitalization and severe outcomes compared to previous variants of SARS-CoV-2. This study, enrolling all COVID-19 adults admitted to a reference hospital who underwent both the S-gene-target-failure test and VOC identification by Sanger sequencing, aimed to describe the evolving prevalence of Delta and Omicron variants and to compare the main in-hospital outcomes of severity, during a trimester (December 2021 to March 2022) of VOCs' cocirculation. Factors associated with clinical progression to noninvasive ventilation (NIV)/mechanical ventilation (MV)/death within 10 days and to MV/admission to intensive care unit (ICU)/death within 28 days, were investigated through multivariable logistic regressions. Overall, VOCs were: Delta n = 130/428, Omicron n = 298/428 (sublineages BA.1 n = 275 and BA.2 n = 23). Until mid-February, Delta predominance shifted to BA.1, which was gradually displaced by BA.2 until mid-March. Participants with Omicron VOC were more likely to be older, fully vaccinated, with multiple comorbidities and to have a shorter time from symptoms' onset, and less likely to have systemic symptoms and respiratory complications. Although the need of NIV within 10 days and MV within 28 days from hospitalization and the admission to ICU were less frequent for patients with Omicron compared to those with Delta infections, mortality was similar between the two VOCs. In the adjusted analysis, multiple comorbidities and a longer time from symptoms' onset predicted 10-day clinical progression, while complete vaccination halved the risk. Multimorbidity was the only risk factor associated with 28-day clinical progression. In our population, in the first trimester of 2022, Omicron rapidly displaced Delta in COVID-19 hospitalized adults. Clinical profile and presentation differed between the two VOCs and, although Omicron infections showed a less severe clinical picture, no substantial differences for clinical progression were found. This finding suggests that any hospitalization, especially in more vulnerable individuals, may be at risk for severe progression, which is more related to the underlying frailty of patients than to the intrinsic severity of the viral variant.

Identifiants

pubmed: 37246793
doi: 10.1002/jmv.28831
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28831

Informations de copyright

© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952-954. doi:10.1016/S0140-6736(21)00370-6
Dyson L, Hill EM, Moore S, et al. Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. Nat Commun. 2021;12(1):5730. doi:10.1038/s41467-021-25915-7
World Health Organization. Tracking SARS-CoV-2 variants. Accessed April 30, 2022. https://www.who.int/activities/tracking-SARS-CoV-2-variants
ECDC SARS COV-2 Variant of Concerns. Accessed April 30, 2022. https://www.ecdc.europa.eu/en/covid-19/variants-concerns
Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162-177. doi:10.1038/s41579-022-00841-7
Yu C, Qianyun L, Li Z, et al. Emerging SARS-CoV-2 variants: why, how, and what's next? Cell Insight. 2022;1(3):100029. doi:10.1016/j.cellin.2022.100029
Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94(7):2986-3005. doi:10.1002/jmv.27717
Magiorkinis G. On the evolution of SARS-CoV-2 and the emergence of variants of concern. TIM. 2023;31(1):5-8. doi:10.1016/j.tim.2022.10.008
DeGrace MM, Ghedin E, Frieman MB, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605:640-652. doi:10.1038/s41586-022-04690-5
World Health Organization. Update on Omicron. Accessed April 30, 2022. https://www.who.int/news/item/28-11-2021-update-on-omicron
World Health Organization. Weekly epidemiological update on COVID-19-22 March 2022. Accessed April 30, 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2022
Jørgensen SB, Nygård K, Kacelnik O, Telle K. Secondary attack rates for omicron and delta variants of SARS-CoV-2 in Norwegian households. JAMA. 2022;327(16):1610-1611. doi:10.1001/jama.2022.3780
Eggink D, Andeweg SP, Vennema H, et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022;27(4):2101196. doi:10.2807/1560-7917.ES.2022.27.4.2101196
Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med. 2022;386(16):1579-1580. doi:10.1056/NEJMc2201849
Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529)-variant of concern-molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021;25(24):8019-8022. doi:10.26355/eurrev_202112_27653
Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126-2128. doi:10.1016/S0140-6736(21)02758-6
Chavda V, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and omicron variants of SARS-CoV-2: what we know so far. Vaccines. 2022;10(11):1926. doi:10.3390/vaccines10111926
Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM, Apostolopoulos V. Therapeutics to tackle Omicron outbreak. Immunotherapy. 2022;14(11):833-838. doi:10.2217/imt-2022-0064
Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7
Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-446. doi:10.1016/S0140-6736(22)00017-4
Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of patients infected with delta versus Omicron COVID-19 variants presenting to Paris emergency departments: a retrospective cohort study. Ann Intern Med. 2022;175(6):831-837. doi:10.7326/M22-0308
Fall A, Eldesouki RE, Sachithanandham J, et al. The displacement of the SARS-CoV-2 variant Delta with omicron: an investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022;79:104008. doi:10.1016/j.ebiom.2022.104008
Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of Covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378:e070695. doi:10.1136/bmj-2022-070695
Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis. 2022;22(7):967-976. doi:10.1016/S1473-3099(22)00154-2
Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327(6):583-584. doi:10.1001/jama.2021.24868
Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 2022;116:38-42. doi:10.1016/j.ijid.2021.12.357
World Health Organization. Severity of Disease Associated with Omicron Variant as Compared with Delta Variant in Hospitalized Patients with Suspected or Confirmed SARS-CoV-2 Infection. World Health Organization; 2022.
Van Goethem N, Chung PYJ, Meurisse M, et al. Clinical severity of SARS-CoV-2 omicron variant compared with delta among hospitalized COVID-19 patients in Belgium during autumn and winter season 2021-2022. Viruses. 2022;14(6):1297. doi:10.3390/v14061297
Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study medRxiv; 2022.
Sberna G, Fabeni L, Berno G, et al. Rapid and qualitative identification of SARS-CoV-2 mutations associated with variants of concern using a multiplex RT-PCR assay coupled with melting analysis. Int J Infect Dis. 2022;122:401-404.
Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30(4):772-780. doi:10.1093/molbev/mst010
Khare S, Gurry C, Freitas L, et al. GISAID's role in pandemic response. China CDC Weekly. 2021;3(49):1049-1051. doi:10.46234/ccdcw2021.255
Romeo I, Prandi IG, Giombini E, et al. The spike mutants website: a worldwide used resource against SARS-CoV-2. Int J Mol Sci. 2022;23(21):13082. doi:10.3390/ijms232113082
Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268-274. doi:10.1093/molbev/msu300
Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nature Methods. 2017;14(6):587-589. doi:10.1038/nmeth.4285
Emma BH. CoVariants: SARS-CoV-2 Mutations and Variants of Interest; 2021. https://covariants.org/
Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022, 376:e069761. doi:10.1136/bmj-2021-069761
Whitaker M, Elliott J, Bodinier B, et al. Variant-Specific Symptoms of COVID-19 among 1,542,510 People in England; 2022. doi:10.1101/2022.05.21.22275368
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet. 2022;399(10335):1618-1624. doi:10.1016/S0140-6736(22)00327-0
Fonager J, Bennedbaek M, Bager P, et al. Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. Euro Surveill. 2022;27(10):2200181. doi:10.2807/1560-7917.ES.2022.27.10.2200181
Wolter N, Jassat W, von Gottberg A, Cohen C. Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa. Lancet. 2022;400(10346):93-96. doi:10.1016/S0140-6736(22)00981-3
Laitman AM, Lieberman JA, Hoffman NG, Roychoudhury P, Mathias PC, Greninger AL. The SARS-CoV-2 omicron variant does not have higher nasal viral loads compared to the Delta variant in symptomatic and asymptomatic individuals. J Clin Microbiol. 2022;60(4):e0013922. doi:10.1128/jcm.00139-22
Berno G, Fabeni L, Matusali G, et al. SARS-CoV-2 variants identification: overview of molecular existing methods. Pathogens. 2022;11(9):1058. doi:10.3390/pathogens11091058
Feikin DR, Abu-Raddad LJ, Andrews N, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Vaccine. 2022;40(26):3516-3527. doi:10.1016/j.vaccine.2022.04.069

Auteurs

Annalisa Mondi (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Ilaria Mastrorosa (I)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Pierluca Piselli (P)

Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Claudia Cimaglia (C)

Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Giulia Matusali (G)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Fabrizio Carletti (F)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Giuseppina Giannico (G)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Eugenia Milozzi (E)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Elisa Biliotti (E)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Silvia Di Bari (S)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Pierangelo Chinello (P)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Alessia Beccacece (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Francesca Faraglia (F)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Pietro Vittozzi (P)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Silvia Mosti (S)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Nardi Tetaj (N)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Giulia Valeria Stazi (GV)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Carmela Pinnetti (C)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Marta Camici (M)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Alberto D'Annunzio (A)

Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Alessandra Marani (A)

Health Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Lavinia Fabeni (L)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Eliana Specchiarello (E)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Cesare Ernesto Maria Gruber (CEM)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Alberta Villanacci (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Sabrina Minicucci (S)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Anna Rosa Garbuglia (AR)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Stefania Ianniello (S)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Luisa Marchioni (L)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Fabrizio Taglietti (F)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Gianpiero D'Offizi (G)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Fabrizio Palmieri (F)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Emanuele Nicastri (E)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Fabrizio Maggi (F)

Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Francesco Vaia (F)

General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Enrico Girardi (E)

Department of Epidemiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Andrea Antinori (A)

Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH